Eli Lilly (LLY) has joined the trillion-dollar club with a market capitalization crossing $1 trillion, a rare feat for a drug maker. The company’s focus on developing and marketing drugs for obesity and diabetes has propelled its growth. However, with the stock up over 600% in the past 5 years, questions arise about valuation and long-term sustainability. LLY’s stock trades at 43x forward earnings and 22x sales, indicating it is not cheap by traditional metrics. Technical analysis shows the stock has experienced significant price fluctuations, signaling potential risks ahead. Risk managers are considering protective strategies like collars to safeguard gains while staying invested. Options collars offer a balanced tradeoff between upside and downside risk, providing control over the investment’s outcome. As LLY and similar stocks reach new heights, understanding and implementing collars can help manage risk and maximize returns.

Read more at Barchart: Eli Lilly’s Stock Price Has Fattened Up Like a Thanksgiving Turkey. Time to (Options) Collar That Green!